Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | DDO | Q99489 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564609 | 0.70 | CYP2A6 (0.35) | CYP2A6SLC6A3SLC6A4MDM2KDM4E | |
| SCHEMBL4949929 | 0.69 | CYP2A6 (0.41) | CYP2A6SLC6A3SLC6A4MAOBAKR1C3 | |
| SCHEMBL12993141 | 0.66 | CYP2A6 (0.44) | CYP2A6POLBSMN1; SMN2SLC6A3SLC6A4 | |
| SCHEMBL9027058 | 0.65 | AOC3 (0.44) | CYP2A6SLC6A3SLC6A4CA2PTPN2 | |
| SCHEMBL3260435 | 0.65 | CYP2A6 (0.37) | CYP2A6SLC6A3SLC6A4CA2FLT3 | |
| SCHEMBL2347853 | 0.62 | POLB (0.63) | POLBSMN1; SMN2PTPN2PTPN1FLT3 | |
| SCHEMBL73543 | 0.61 | AOC3 (0.47) | CYP2A6SLC6A3SLC6A4CA2FLT3 | |
| SCHEMBL28550307 | 0.61 | AOC3 (0.42) | CYP2A6POLBSMN1; SMN2SLC6A3SLC6A4 | |
| SCHEMBL13634946 | 0.61 | CHRNB2 (0.50) | HRH3 | |
| SCHEMBL13162089 | 0.61 | HRH3 (0.42) | CA2AKR1C3AOC3HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008340-B2 | 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1791537-B1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20070142454-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1791537-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006023590-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142454-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | CSNK1A1, CSNK1E, CSNK1D | CYP2A6 2473/4885POLB 2007/4885SMN1; SMN2 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.